Evidence map›Paper›PMID 29721214›Full record

ReviewOncotarget2018

Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology.

Magdalena Cisło, Agata Anna Filip, George Johan Arnold Offerhaus, Bogumiła Ciseł, Karol Rawicz-Pruszyński, Małgorzata Skierucha, Wojciech Piotr Polkowski

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 128 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Identifying early warning signals of cancer formation.Quantitative biology (Beijing, China) · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Magdalena CisłoDepartment of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
Agata Anna FilipDepartment of Cancer Genetics and Cytogenetics Laboratory, Medical University of Lublin, Lublin, Poland.
George Johan Arnold OfferhausDepartment of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Bogumiła CisełDepartment of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
Karol Rawicz-PruszyńskiDepartment of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
Małgorzata SkieruchaDepartment of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
Wojciech Piotr PolkowskiDepartment of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
Medical University of Lublin · PLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Western countries the majority of gastric cancers (GC) are usually diagnosed in advanced stages reporting a 5-year survival rate of only 26%. The Laurén classification of GC was most widely used in clinical practice since it reflects GC morphology, epidemiology, tumor biology, clinical management and outcome. Despite the initial promise of individualizing antitumor treatment, the management of GC still remains relatively broad and general. Apart from clinical staging, molecular profiling enables targeting of the identified underlying alterations, rather than histology. In contrast to breast carcinoma, molecular classification of GC does not yet imply treatment modality. Molecular classifications of GC and their therapeutic implications are therefore extensively studied. The current proposed molecular divisions of GC come from three different parts of the world where different standard treatment modalities for advanced GC are recommended. Wider use of GC molecular subtyping may solve problems, such as susceptibility to novel systemic therapy regimens or selection of patients for aggressive surgery and targeted adjuvant/conversion therapy. In any case, the rapid entry of novel molecular targeted therapies into routine oncology practice clearly underscores the urgent need for clinicians to be aware of these new possibilities.

Indexed as

molecular therapeuticspathologystomach neoplasmsurgical oncology

Identifiers

PMID29721214
PMCPMC5922408
OpenAlexW2798071709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.